Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.

Article  PubMed  PubMed Central  Google Scholar 

Oba M, Hasegawa K, Shindoh J, Yamashita S, Sakamoto Y, Makuuchi M, et al. Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. Surgery. 2016;159:632–40.

Article  PubMed  Google Scholar 

Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27:280–8.

Article  PubMed  Google Scholar 

Sawada Y, Sahara K, Endo I, Sakamoto K, Honda G, Beppu T, et al. Long-term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci. 2020;27:810–8.

Article  PubMed  Google Scholar 

Yamaguchi K, Urakami K, Ohshima K, Mochizuki T, Akiyama Y, Uesaka K, et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses-the Project HOPE. Biomed Res. 2014;35:407–12.

Article  PubMed  CAS  Google Scholar 

Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, et al. Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci. 2020;111:687–99.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.

Article  PubMed  PubMed Central  Google Scholar 

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.

Article  PubMed  Google Scholar 

Yamaguchi T, Kinugasa Y, Shiomi A, Kagawa H, Yamakawa Y, Furuatni A, et al. Short- and long-term outcomes of robotic-assisted laparoscopic surgery for rectal cancer: results of a single high-volume center in Japan. Int J Colorectal Dis. 2018;33:1755–62.

Article  PubMed  Google Scholar 

Hino H, Yamaguchi T, Kinugasa Y, Shiomi A, Kagawa H, Yamakawa Y, et al. Robotic-assisted multivisceral resection for rectal cancer: short-term outcomes at a single center. Tech Coloproctol. 2017;21:879–86.

Article  PubMed  CAS  Google Scholar 

Yamaoka Y, Shiomi A, Kagawa H, Hino H, Manabe S, Kato S, et al. Robotic surgery for clinical T4 rectal cancer: short- and long-term outcomes. Surg Endosc. 2022;36:91–9.

Article  PubMed  Google Scholar 

Ito T, Sugiura T, Okamura Y, Yamamoto Y, Ashida R, Uesaka K. The impact of posthepatectomy liver failure on long-term survival after hepatectomy for colorectal liver metastasis. HPB (Oxford). 2019;21:1185–93.

Article  PubMed  Google Scholar 

Kanemitsu Y, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D, et al. Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clin Oncol. 2021;39:3789–99.

Article  PubMed  CAS  Google Scholar 

Shimoda Y, Nagashima T, Urakami K, Tanabe T, Saito J, Naruoka A, et al. Integrated next-generation sequencing analysis of whole exome and 409 cancer-related genes. Biomed Res. 2016;37:367–79.

Article  PubMed  CAS  Google Scholar 

Nagashima T, Shimoda Y, Tanabe T, Naruoka A, Saito J, Serizawa M, et al. Optimizing an ion semiconductor sequencing data analysis method to identify somatic mutations in the genomes of cancer cells in clinical tissue samples. Biomed Res. 2016;37:359–66.

Article  PubMed  Google Scholar 

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.

Article  PubMed  CAS  Google Scholar 

Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, et al. Association between specific mutations in KRAS Codon 12 and colorectal liver metastasis. JAMA Surg. 2015;150:722–9.

Article  PubMed  PubMed Central  Google Scholar 

Pikoulis E, Papaconstantinou D, Pikouli A, Wang J, Theodoridis C, Margonis GA. Reevaluating the prognostic value of RAS mutation status in patients with resected liver metastases from colorectal cancer: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci. 2021;28:637–47.

Article  PubMed  Google Scholar 

Shindoh J, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K, et al. KRAS mutation status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of Location of the Primary Lesion. Ann Surg Oncol. 2016;23:1890–6.

Article  PubMed  Google Scholar 

Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer. 2016;122:2698–707.

Article  PubMed  CAS  Google Scholar 

Chuang SC, Huang CW, Chen YT, Ma CJ, Tsai HL, Chang TK, et al. Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver-only and lung-only metastases. Oncol Lett. 2020;20:2119–30.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60:6750–6.

PubMed  CAS  Google Scholar 

Renaud S, Guerrera F, Seitlinger J, Costardi L, Schaeffer M, Romain B, et al. KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer. Oncotarget. 2017;8:2514–24.

Article  PubMed  Google Scholar 

Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945–50.

Article  PubMed  CAS  Google Scholar 

Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351:604–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor. J Med Chem. 2022;65:3123–33.

Article  PubMed  CAS  Google Scholar 

Wolff RK, Hoffman MD, Wolff EC, Herrick JS, Sakoda LC, Samowitz WS, et al. Mutation analysis of adenomas and carcinomas of the colon: early and late drivers. Genes Chromosomes Cancer. 2018;57:366–76.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xu Z, Xiang L, Wang R, Xiong Y, Zhou H, Gu H, et al. Bioinformatic analysis of immune significance of RYR2 mutation in breast cancer. Biomed Res Int. 2021;2021:8072796.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Chen Y, Zhang L, Xiong J, Xu L, Cheng C, et al. Ryanodine receptor (RYR) mutational status correlates with tumor mutational burden, age and smoking status and stratifies non-small cell lung cancer patient prognosis. Transl Cancer Res. 2022;11:2070–83.

Article  PubMed  PubMed Central  CAS  Google Scholar